Pravastatin, which is used to tackle high cholesterol levels may also slow down the growth of kidney cysts in individuals with autosomal dominant polycystic kidney disease, a new study found.
ADPKD is the most common potentially lethal hereditary kidney disease, affecting at least 1 in 1000 people. ADPKD is characterized by progressive kidney enlargement due to cyst growth, which results in loss of kidney function over time. At one time, ADPKD was termed "adult" polycystic kidney disease but researchers are finding that clinical manifestations may be evident in childhood and even in utero. This strongly suggests that earlier intervention in childhood may have the greatest long term effect on the progression of the disease.
LDL Cholesterol-Lowering Therapy can Reduce Risk of Heart Disease, Stroke in Kidney Disease Patients
Through statin-based treatment, lowering LDL cholesterol did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Advertisement
"Based on our findings, we strongly recommend consideration of pravastatin use in ADPKD children and young adults unless there is a medical reason against taking a statin as determined by the patients' doctor," says the co-principal investigator Melissa A. Cadnapaphornchai, MD, from CU School of Medicine's departments of pediatrics & medicine, who conducted the study with Robert W. Schrier, MD, at the CU School of Medicine. "This is very exciting news as this is the first medication shown to help control kidney disease in ADPKD children."
The three-year study began with 110 children/young adults ages 8 to 22 years with ADPKD and finished with 92 participants. Each participant was randomized to receive either pravastatin or placebo completely by chance by a procedure similar to the toss of a coin. Treatment with pravastatin was associated with no significant side effects. However, it should not be used during pregnancy
![Prenatal Risk Factors Increase Risk of Kidney Disease in Children]( "Prenatal Risk Factors Increase Risk of Kidney Disease in Children")
A study suggests that certain prenatal risk factors are associated with the development of chronic kidney disease in children.
The researchers emphasize that pravastatin is not FDA-approved for the treatment of ADPKD; therefore, it is essential that patients discuss the potential risks and benefits of treatment, including possible psychosocial and financial implications, with their doctor.
Source: Eurekalert
Prenatal Risk Factors Increase Risk of Kidney Disease in Children
A study suggests that certain prenatal risk factors are associated with the development of chronic kidney disease in children.
Advertisement
The researchers emphasize that pravastatin is not FDA-approved for the treatment of ADPKD; therefore, it is essential that patients discuss the potential risks and benefits of treatment, including possible psychosocial and financial implications, with their doctor.
Source: Eurekalert
CDx Test for Diabetic Kidney Disease to be Revealed Soon
The development of a companion diagnostic (CDx) test with the validation of several of its protein biomarkers is an important milestone completed by Protcomics International
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
The discovery deepens our understanding of m6A biology and stress granule formation, with implications for neurodegenerative diseases.
Trouble with sleep and the body's clock may increase your risk for Parkinson's, as per a new study.
New study uncovers a link between nocturnal hot flashes and Alzheimer's risk in menopausal women, suggesting a potential biomarker.
Our discovery revealed that a minority of individuals attributed their chronic pain to their brain's involvement.
Relative Energy Deficiency in Sport syndrome is overlooked by athletes and can be worsened by 'sports culture' due to its perceived short-term performance benefits.
